KROMATID Joins CIRM's Industry Resource Partnership Program to Enhance Genomic Analysis

KROMATID Selected as Industry Resource Partner by CIRM

KROMATID, a prominent player in the field of analytical cytogenetics, has recently been acknowledged by the California Institute for Regenerative Medicine (CIRM) as a member of its Industry Resource Partnership (IRP) program. This significant partnership aims to enhance collaboration between industry members and CIRM researchers, streamlining access to crucial resources for both non-clinical and clinical development within the realm of cell and gene therapy.

The IRP program specifically facilitates knowledge sharing, which is vital for researchers aiming to develop groundbreaking therapies. As part of this collaboration, KROMATID will provide CIRM-funded scientists with access to cutting-edge, high-resolution single-cell genomic structure analysis. This capability is essential in understanding the intricate structural variations within genomes, which can greatly impact the efficacy and safety of therapies under development.

KROMATID's innovative platform allows researchers to obtain a direct, single-cell perspective on genomic structures. This technology is pivotal for confirming findings derived from sequencing data, helping to identify and characterize various genomic alterations such as chromosomal abnormalities and copy number variations. With this comprehensive insight, developers in the cell and gene therapy sector can gain a deeper understanding of cellular changes throughout the development process.

CEO Matt Hemstreet highlighted the historical underutilization of advanced cytogenetic techniques in evaluating living drug therapies. He remarked, "That information can be valuable much earlier in development, when researchers are still making decisions about starting material, editing, and process development." The aim is not only to ensure that the cells involved are genomically intact but also to determine whether they are fit for therapeutic use.

KROMATID's commitment to offering precise genomic insights is reflected in their stringent analytical methods, combining proprietary imaging with advanced bioinformatics. These processes enable developers to advance therapies confidently, through discovery phases all the way to regulatory approvals. The work with CIRM is expected to propel awardees beyond basic genomic assessments, fostering an environment where the genomic fitness of cells can be thoroughly analyzed.

As the field of regenerative medicine rapidly evolves, partnerships like the one between KROMATID and CIRM are critical. They embody a transformative shift towards precision medicine, where scientific rigor meets innovative technology. By collaborating with CIRM, KROMATID aims to play a pivotal role in developing next-generation therapies that address unmet medical needs, benefiting patients both in California and worldwide.

About KROMATID

Founded with a mission to provide unparalleled clarity in chromosomal integrity analysis, KROMATID stands at the forefront of the cell and gene therapy landscape. Through its proprietary technologies, it empowers developers with the tools necessary to navigate the complexities of genomic alterations effectively.

About CIRM

The California Institute for Regenerative Medicine is a state agency that has committed billions towards accelerating stem cell and gene therapies. Since its inception in 2004, CIRM has paved the way for transformative medical breakthroughs, continually striving to strengthen California's position as a hub for biotechnology and regenerative medicine.

For further information on KROMATID and its innovative solutions, visit www.kromatid.com. For more insights about CIRM and its mission, explore www.cirm.ca.gov.